Evidence-Based Practice Module 6

Activity Preview

This activity is intended for BCACPs in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This series will feature succinct commentaries about practice-changing evidence through a series of podcasts, articles. online panel discussions, and polls. This module consists of 4 activities and offers 2 hours of continuing pharmacy education and/or recertification credit. These activities are produced in conjunction with iForumRx and are part of the APhA professional development program for BCACP recertification approved by BPS.

Additional Modules can be found here: Evidence-Based Practice Podcast and Literature Series.

Learning Objectives

At the completion of this activity, the participant will be able to:

Going Up in Flames: Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease Receiving Anticoagulation for Atrial Fibrillation

  • State the rationale, methodology, findings, limitations, and implications of the AFIRE study of rivaroxaban with or without an antiplatelet agent in patients with atrial fibrillation and stable coronary artery disease.
  • Formulate recommendations for the use of antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease based on the findings of the AFIRE trial.
  • Formulate recommendations for the use of rivaroxaban in patients with atrial fibrillation and stable coronary artery disease.

Cardiovascular Safety for Allopurinol and Febuxostat: Getting to the Heart of the Matter!

  • Explain the key strengths, weaknesses, and findings from the Cardiovascular safety of febuxostat or allopurinol in patients with gout (CARES) trial.
  • Determine when it is appropriate to use febuxostat in patients with gout and cardiovascular disease.
  • Recommend appropriate non-pharmacologic and pharmacologic therapies for the treatment and prevention of gout.

A Cause for a PAUSE: Evaluating the Safety and Efficacy of a Standardized Perioperative DOAC Management Protocol

  • Differentiate between various guideline recommendations for perioperative management of patients receiving a direct oral anticoagulant for atrial fibrillation.
  • Evaluate the safety and efficacy of a standardized perioperative management approach that is easy to use and does not require preoperative coagulation function testing.
  • Design a perioperative management plan for a patient receiving a direct oral anticoagulant based on procedural bleed risk, specific agent pharmacokinetic, and estimated creatinine clearance.

Age is Not Just a Number: Discontinue Statins with Care

  • Critically analyze the research methodology of existing clinical literature on statin therapy for primary atherosclerotic cardiovascular disease prevention in older adults
  • Interpret clinical literature describing the risk versus benefit of statin therapy for primary atherosclerotic cardiovascular disease prevention in older adults
  • Recommend lipid-lowering therapy for adults = 75 years of age according to the 2018 American College of Cardiology-American Heart Association Guideline on the Management of Blood Cholesterol

Activity type: Application-based
Target Audience: Pharmacists 
Learning level: 2

Accreditation Information

ACPE Logo

The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  This activity is approved for 2 contact hours of CPE credit (0.2 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-20-197-H04-P.

To obtain 2 contact hours of CPE credit (0.2 CEUs) for Evidence-Based Practice Module 6, complete the learning activities, assessment with a grade of 70% or better, and evaluation questions.

Per Board of Pharmacy Specialties (BPS) requirements, you will have one opportunity to successfully complete this continuing pharmacy education assessment. Please note that you will not be permitted to submit the assessment a second time. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.

You do not need to complete assessment in one sitting. Once successfully completed, you will be able to claim credit. Participants will need to have a valid APhA (pharmacist.com) username and password, as well as a CPE Monitor account to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.

Initial release date: May 10, 2020
Expiration date: May 10, 2023 - Credit cannot be earned after this date

Development

Evidence-Based Practice Module 6 is an online educational activity for pharmacists developed by the American Pharmacists Association. © 2020 American Pharmacists Association

Disclosures

APhA’s editorial staff declares no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, visit the APhA website at www.pharmacist.com/apha-disclosures

Conflicts of interest have been resolved through content review by Helen Sairany, BA, PharmD, MBA, BCACP, Director of Content Development & Partnership at the American Pharmacists Association. 

Fee

Member: $40
Non-member: $70

System Requirements

Computer and internet access are required to complete this activity.  Please visit our website to view the Technology System Requirements in order to have a positive learning experience.

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE# 0202-0000-20-197-H04-P 0.2 CEUs May 10, 2020 - May 10, 2023
0202-0000-20-197-H04-P 2 Hours May 10, 2020 - May 10, 2023